---
title: "Mereo BioPharma and Sentynl Therapeutics sign licensing deal for alvelestat"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295643755.md"
description: "Mereo BioPharma and Sentynl Therapeutics signed a licensing deal for alvelestat. Sentynl acquires exclusive US commercial rights via an option, paying a non-refundable fee. Upon exercise, Mereo receives up to $40m upfront/R&D payments, up to $435m in milestones, and double-digit royalties. Sentynl holds global manufacturing rights and funds Phase III development starting early 2027. Alvelestat targets AATD-LD with orphan drug designations."
datetime: "2026-08-12T09:14:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295643755.md)
  - [en](https://longbridge.com/en/news/295643755.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295643755.md)
generator: "portal-rs"
---

# Mereo BioPharma and Sentynl Therapeutics sign licensing deal for alvelestat

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [MREO.US](https://longbridge.com/en/quote/MREO.US.md)

## Related News & Research

- [Kevin O’Leary declared 'inflation affects all of us' while shopping for Walmart paper towel bargains. How to fight back](https://longbridge.com/en/news/306393334.md)
- [Anthropic PBC (ANT) Claims Claude Solved The 167 Year Old Riemann Hypothesis](https://longbridge.com/en/news/306374461.md)
- [Wall St Week Ahead-'Black Friday' brings consumer spending into focus for AI-rocked market](https://longbridge.com/en/news/306395310.md)
- [Cummins (CMI) Stock Could Be 48% Undervalued Despite New Mining Engine Launch](https://longbridge.com/en/news/306392028.md)
- [Is 3D Printing Tie Up Altering The Investment Case For HP (HPQ)?](https://longbridge.com/en/news/306391924.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**